Results 81 to 90 of about 1,064,547 (319)

Modulation of Biological Membranes Using Small-Molecule Compounds to Counter Toxicity Caused by Amyloidogenic Proteins

open access: yesMembranes
The transition of peptides or proteins along a misfolding continuum from soluble functional states to pathological aggregates, to ultimately deposit as amyloid fibrils, is a process that underlies an expanding group of human diseases—collectively known ...
Raina Marie Seychell   +2 more
doaj   +1 more source

T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Hemophilic arthropathy remains the leading morbidity in hemophilia despite modern prophylaxis, and early joint damage may be missed by routine exams. This study explored T2* MRI as a noninvasive biomarker of hemosiderin deposition in pediatric hemophilia.
Jessica Garcia   +6 more
wiley   +1 more source

Therapeutics Letter 11 [PDF]

open access: yes, 1995
Therapeutics Letter 11 reviews the treatment of transient and chronic insomnia in the primary care setting. Conclusions: Manage insomnia in your practice by education and encouragement of appropriate sleep habits.
Therapeutics Initiative (University of British Columbia)
core  

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation

open access: yesHealth Technology Assessment
Background Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through newborn screening and causes symptoms throughout the body, including the lungs and digestive system ...
Steven J Edwards   +7 more
doaj   +1 more source

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan   +14 more
wiley   +1 more source

Therapeutics Letter 66 [PDF]

open access: yes, 2007
Therapeutics Letter 66 provides an update on the prescription drug treatments for overactive bladder that were previously reviewed in Therapeutics Letter 57.
Therapeutics Initiative (University of British Columbia)
core  

Circulating Extracellular Vesicles: An Effective Biomarker for Cancer Progression

open access: yesFrontiers in Bioscience-Landmark
Extracellular vesicles (EVs), the ubiquitous part of human biology, represent a small heterogenous, membrane-enclosed body that contains a diverse payload including genetic materials in the form of DNA, RNAs, small non-coding RNAs, etc.
Madhura Chatterjee   +6 more
doaj   +1 more source

OPTIMISTIC THERAPEUTICS [PDF]

open access: yesJournal of the American Medical Association, 1911
n ...
openaire   +2 more sources

Childhood Acute Lymphoblastic Leukemia Survival in Western Kenya: Reduction in Early Deaths and Treatment Abandonment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background An earlier study on children diagnosed with acute lymphoblastic leukemia (ALL) at Moi Teaching and Referral Hospital (MTRH) in Kenya reported a low event‐free survival (EFS), excess treatment abandonment, and high induction mortality.
Gilbert Olbara   +7 more
wiley   +1 more source

Therapeutics Letter 7 [PDF]

open access: yes, 1995
Therapeutics Letter 7 examines drugs of choice for the treatment of hypertension. Conclusions: based on the evidence available at this time and using criteria of effectiveness and cost, thiazides are clearly the drug of first choice.
Therapeutics Initiative (University of British Columbia)
core  

Home - About - Disclaimer - Privacy